CanSino Biologics (HKG:6185, SHA:688185) will receive a further $17 million grant from Bill & Melinda Gates Foundation for the continued development of the recombinant poliomyelitis vaccine (CS-2036), a Wednesday bourse filing said.
The Chinese biotechnology firm had initially obtained $2 million of funding from the foundation in October 2023.
The further development included clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidates
Shares of the company closed over 8% lower on Wednesday.
Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments